Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
Type:
Application
Filed:
November 14, 2013
Publication date:
May 1, 2014
Applicants:
MEDAREX, L.L.C., UNIVERSITY OF MASSACHUSETTS
Inventors:
Donna M. AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
Type:
Grant
Filed:
August 7, 2013
Date of Patent:
April 29, 2014
Assignees:
Amgen Inc., Medarex, L.L.C.
Inventors:
Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliot
Abstract: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step.
Type:
Grant
Filed:
March 2, 2012
Date of Patent:
April 15, 2014
Assignee:
Medarex, L.L.C.
Inventors:
Alahari Arunakumari, Gisela M. Ferreira
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
Type:
Grant
Filed:
July 17, 2008
Date of Patent:
March 25, 2014
Assignee:
Medarex, L.L.C.
Inventors:
Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi Leblanc, Timothy Sproul, Mark Yamanaka
Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
Type:
Application
Filed:
September 19, 2013
Publication date:
January 16, 2014
Applicant:
MEDAREX, L.L.C.
Inventors:
Jennifer Marie MATARAZA, Andrea VAN ELSAS, Alan J. KORMAN, Edward L. HALK, Kent B. THUDIUM, Mark J. SELBY, Timothy W. SPROUL, Heidi N. LEBLANC
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.
Type:
Grant
Filed:
December 8, 2006
Date of Patent:
December 17, 2013
Assignee:
Medarex, L.L.C.
Inventors:
Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison Witte, Haichun Huang
Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
Type:
Grant
Filed:
June 7, 2012
Date of Patent:
December 17, 2013
Assignees:
University of Massachusetts, Medarex, L.L.C.
Inventors:
Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.
Type:
Grant
Filed:
July 19, 2012
Date of Patent:
November 12, 2013
Assignee:
Medarex, L.L.C.
Inventors:
Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
Type:
Grant
Filed:
May 2, 2012
Date of Patent:
July 23, 2013
Assignee:
Medarex, L.L.C.
Inventors:
Josephine M. Cardarelli, Amelia Nancy Black